Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748469 | 0.86 | TDP1 (0.34) | TDP1 | |
| SCHEMBL16579841 | 0.83 | KDM4E (0.39) | — | |
| SCHEMBL18666851 | 0.83 | LATS1 (0.32) | — | |
| SCHEMBL22460653 | 0.80 | — | — | |
| SCHEMBL13104580 | 0.78 | KDM4E (0.45) | TDP1 | |
| SCHEMBL24340763 | 0.78 | KDM4E (0.32) | — | |
| SCHEMBL19594799 | 0.76 | LMNA (0.31) | — | |
| SCHEMBL284757 | 0.76 | NUDT1 (0.34) | — | |
| SCHEMBL23482831 | 0.75 | MEN1 (0.32) | — | |
| SCHEMBL22451580 | 0.74 | TDP1 (0.31) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020190734-A1 | IMMUNOCONJUGATES TARGETING PD-L1 | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190762-A1 | MACROMOLECULE-SUPPORTED TLR AGONISTS | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2015038493-A1 | SYNTHESIS OF NOVEL ASYMMETRIC BOW-TIE PAMAM DENDRIMER-BASED CONJUGATES FOR TUMOR-TARGETING DRUG DELIVERY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | TLR8, TLR7, TLR9 | TDP1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.